Zenas Biopharma(ZBIO.US)

Last Updated 19:00:00 ET
longbridge loading

Tuesday 5/19 Insider Buying Report: ZBIO, ICFI

nasdaq·
US
ZBIO
+5.50%
US
ICFI
+3.15%
nasdaq·
US
ZBIO
+5.50%
US
ICFI
+3.15%

Zenas BioPharma To Present INDIGO Phase 3 Data At EULAR 2026; Wedbush Sees $45 Target

nasdaq·
US
ZBIO
+5.50%
nasdaq·
US
ZBIO
+5.50%

Zenas BioPharma Insider Bought Shares Worth $1,012,800, According to a Recent SEC Filing

Fidelity·
US
ZBIO
+5.50%
Fidelity·
US
ZBIO
+5.50%

Zenas BioPharma Announces Upcoming Presentation of Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) at EULAR 2026 Congress | ZBIO Stock News

StockTitan·
US
ZBIO
+5.50%
StockTitan·
US
ZBIO
+5.50%

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Unusual Whales·
US
ZBIO
+5.50%
Unusual Whales·
US
ZBIO
+5.50%

How Zenas BioPharma’s First-in-Human Oral IL-17 Trial Could Reframe Zenas BioPharma (ZBIO) Investors

Simplywall·
US
ZBIO
+5.50%
Simplywall·
US
ZBIO
+5.50%

Zenas BioPharma Announces First Subject Dosed in Phase 1 Clinical Trial of ZB021, a Novel, Potentially Best-in-Class Oral IL-17AA/AF Inhibitor | ZBIO Stock News

StockTitan·
US
ZBIO
+5.50%
US
ARKG
+0.04%
US
PBE
+0.11%
StockTitan·
US
ZBIO
+5.50%
US
ARKG
+0.04%
US
PBE
+0.11%

Zenas BioPharma, Inc. 1Q 2026: Revenue $16.91M, EPS ($1.46) — 10-Q Summary

TradingView·
US
ZBIO
+5.50%
TradingView·
US
ZBIO
+5.50%

Zenas BioPharma Highlights Strong Q1 Progress and Financing

Tip Ranks·
US
ZBIO
+5.50%
Tip Ranks·
US
ZBIO
+5.50%
© 2026 Longbridge｜Disclaimer